Humanized OATP1B1/1B3 Mouse

Constitutive Knockout/Random Transgenic

Humanized OATP1B1/1B3 Constitutive Knockout/Random Transgenic Mouse Model
Live production of model 11594 will cease by March 1, 2020. Contact Taconic Customer Service immediately if you have future needs for this model.

FVB Background

  • Model #
  • Genotype
  • Nomenclature
  • 11594-F
    FVB.129P2-Del(Slco1b2-Slco1a5)1Ahs Tg(APOE-SLCO1B1)1Ahs Tg(APOE-SLCO1B3)1Ahs
  • 11594-M
    FVB.129P2-Del(Slco1b2-Slco1a5)1Ahs Tg(APOE-SLCO1B1)1Ahs Tg(APOE-SLCO1B3)1Ahs
  • This model carries a deletion of all five established Slco1a and 1b and two predicted Slco1a-like mouse genes as well as random transgenic insertions of human SLCO1B1 (OATP1B1) and SLCO1B3 (OATP1B3) under control of the liver specific ApoE promoter.
  • Contains a cre-mediated deletion of the following established genes in the Slco1a/1b cluster: Slco1a1, Slco1a4, Slco1a5, Slco1a6 and Slco1b2.
  • SLCO1B1 (OATP1B1) and SLCO1B3 (OATP1B3) are important hepatic uptake transporters that can transport a wide variety of drugs, such as many statins.
  • Useful in dissecting the role of human OATP1B1 and OATP1B3 in hepatic liver uptake, drug-drug interaction, drug-induced hyperbilirubinemia and drug toxicity.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

FVB/N Background


The Oatp1a/1b Cluster Knockout Mouse was developed in the laboratory of Alfred Schinkel of the Netherlands Cancer Institute in 2010. The model was generated by insertion of loxP sites into the Slco1a5 and Slco1b2 genes at both ends of the Slco1a/1b gene cluster in E14 embryonic stem cells derived from 129P2/OlaHsd mice, followed by Cre-mediated deletion and injecting the targeted cells into C57BL/6J blastocysts. Resultant chimeras were backcrossed to FVB/N mice. Expression of human OATP1B1 and 1B3 in the liver of transgenic mice was achieved by constructing an ApoE promoter-HCR1-driven expression cassette containing either human SLCO1B1 or SLCO1B3 cDNA followed by pronuclear injection into fertilized oocytes of FVB mice. Two-cell stage embryos were implanted into oviducts of pseudopregnant F1 fosters and carried to term. Founders with stable hepatic expression of either human OATP1B1 or OATB1B3 were selected for further crosses with Oatp1a/1b Cluster Knockout Mouse described above. Taconic received sperate stocks of Humanized OATP1B1 and 1B3 Mice in 2010. Humanized OATP1B1 and 1B3 Mice were derived by embryo transfer and were further crossed by Taconic to generate double Humanized OATP1B1/1B3 Mice. These mice are maintained by incrossing of mice homozygous for the Oatp1a/1b Cluster Knockout, the human OATP1B1 transgene and the human OATP1B3 transgene.


Ordering Note: Around 5 weeks of age and at onset of sexual maturity, males become aggressive and begin to fight. Male mice are shipped in divided Taconic Transit Cages™ with one animal per section. We highly recommend housing the male mice one per cage upon receipt.





Initial Publication:

Salphati L, Chu X, Chen L, Prasad B, Dallas S, Evers R, Mamaril-Fishman D, Geier EG, Kehler J, Kunta J, Mezler M, Laplanche L, Pang J, Rode A, Soars MG, Unadkat JD, van Waterschoot RA, Yabut J, Schinkel AH, Scheer N. (2014) Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins. Drug Metab. Dispos. 42(8):1301-13.

The single humanized models for OATP1B1 and 1B3 were published as follows: van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH (2012). Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res. 2012 Dec 14.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless additional rights have been granted in writing by Taconic.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.